BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Relmada Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 11:56 am Sale | 2022-12-31 | 13G | Relmada Therapeutics, Inc. RLMD | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -1,647,400 (Position Closed) | Filing |
| 2021-12-20 4:51 pm Purchase | 2021-12-09 | 13G | Relmada Therapeutics, Inc. RLMD | BIOTECHNOLOGY VALUE FUND L P | 1,647,400 5.900% | 1,647,400 (New Position) | Filing |